Skip to content

Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients

A Randomized Trial of Immunomodulating Diets With Arginine and Omega-3 Fatty Acids in Renal Transplant Recipients

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00047983
Enrollment
75
Registered
2002-10-24
Start date
Unknown
Completion date
2004-04-30
Last updated
2017-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Diseases

Keywords

Kidney Transplantation, Fatty Acids, Omega-3, Erythrocyte Membrane, Graft Survival

Brief summary

The purpose of this study is to evaluate the effectiveness of nutritional supplements in increasing the amount of omega-3 fatty acids (and arginine) in the red blood cell membranes and plasma of kidney transplant patients, and, secondarily, to compare patient compliance. The long-term goal of this study is to develop low risk therapies that will allow improved and lasting survival of donor tissue with minimal suppression of the immune system.

Detailed description

Short-term survival rates of donor tissue after kidney transplantation have improved significantly in recent years because of improved immunosuppression. Rates of long-term tissue loss have changed less because of a high incidence of chronic rejection, infectious complications, and cardiovascular disease. Data suggest that both early and late complications might be reduced in transplant recipients by dietary intervention to raise levels of omega-3 fatty acids and arginine. Prior to transplantation, participants are randomized to one of three groups. Group 1 participants serve as controls and receive no dietary supplements. Participants in Group 2 receive daily nutritional supplements of arginine and canola oil according to body weight. Group 3 participants receive daily nutritional supplements of arginine and a fish oil emulsion according to body weight. All participants receive a standard, low-fat dietary consultation. The status of participants is evaluated peri-transplant and at 1, 3, 6, and 9 months.

Interventions

DIETARY_SUPPLEMENTCanola oil
DIETARY_SUPPLEMENTArginine
DIETARY_SUPPLEMENTFish oil emulsion

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
4 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* End-stage renal disease. * Candidate to receive a living-related donor, living unrelated donor, or first cadaver kidney with at least 1 HLA mismatch. * Negative crossmatch with the intended donor. * Adults must have moderate to severe hypertension and/or take at least 1 medication for hypertension daily. * Willingness to comply with the dietary supplements, including canola oil, a flavored drink mix, or an orange flavored pudding.

Exclusion criteria

* Pregnancy or breast-feeding. * Women of childbearing age who are not willing or able to practice acceptable methods of contraception. * HIV-positive. * Positive test for HBV E-AG/DNA and HCV. * Received an organ transplant or plan to receive a multiple organ transplant. * Phenylketonuria. * Participation in other investigational studies within 30 days of the renal transplant. * Allergy or anaphylactic reactions to eggs or L-arginine. * ABO blood incompatibility. * Children who have previously received more than 5 blood transfusions. * History of stroke.

Design outcomes

Primary

MeasureTime frame
Increases in omega-3 fatty acid levels in plasma and red blood cell membranes observed in each of the three omega-3 supplements used in this study

Secondary

MeasureTime frame
Compliance rates observed in each of the three study groups

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026